Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
BIVI Quote, Financials, Valuation and Earnings
Last price:
$1.37
Seasonality move
:
-0.31%
Day range:
$1.26 - $1.40
52-week range:
$1.06 - $13.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.54x
Volume:
136.3K
Avg. volume:
109.2K
1-year change:
-89.55%
Market cap:
$10.4M
Revenue:
--
EPS (TTM):
-$3.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
-- | -$0.81 | -- | -82.21% | $12.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.29% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.94% | 9.76% | $88.17 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
$1.38 | $12.00 | $10.4M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.73 | $88.17 | $11.9B | 34.65x | $0.00 | 0% | 3.73x |
|
IMNN
Imunon, Inc.
|
$3.25 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
1.61% | 3.387 | 3.6% | 6.83x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.900 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
8.93% | -0.896 | 5.23% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIVI
BioVie, Inc.
|
-$57.3K | -$6.3M | -78.76% | -80.02% | -- | -$4.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$598.9M | $79.4M | 5.34% | 5.89% | 9.08% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
BioVie, Inc. vs. Competitors
-
Which has Higher Returns BIVI or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of 96.33%. BioVie, Inc.'s return on equity of -80.02% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.77 $19.6M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About BIVI or ACAD?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 769.57%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that BioVie, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe BioVie, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is BIVI or ACAD More Risky?
BioVie, Inc. has a beta of 0.564, which suggesting that the stock is 43.606% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock BIVI or ACAD?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or ACAD?
BioVie, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. BioVie, Inc.'s net income of -$6.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$6.1M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns BIVI or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of 16.99%. BioVie, Inc.'s return on equity of -80.02% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.77 $19.6M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About BIVI or ALNY?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 769.57%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that BioVie, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe BioVie, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is BIVI or ALNY More Risky?
BioVie, Inc. has a beta of 0.564, which suggesting that the stock is 43.606% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock BIVI or ALNY?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or ALNY?
BioVie, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. BioVie, Inc.'s net income of -$6.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$6.1M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns BIVI or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of -5.33%. BioVie, Inc.'s return on equity of -80.02% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.77 $19.6M BMRNBioMarin Pharmaceutical, Inc.68.48% -$0.24 $6.7B -
What do Analysts Say About BIVI or BMRN?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 769.57%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that BioVie, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe BioVie, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is BIVI or BMRN More Risky?
BioVie, Inc. has a beta of 0.564, which suggesting that the stock is 43.606% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock BIVI or BMRN?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or BMRN?
BioVie, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. BioVie, Inc.'s net income of -$6.1M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 3.73x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$6.1M BMRNBioMarin Pharmaceutical, Inc.3.73x 34.65x $874.6M -$46.6M
-
Which has Higher Returns BIVI or IMNN?
Imunon, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -80.02% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.77 $19.6M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About BIVI or IMNN?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 769.57%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 561.54%. Given that BioVie, Inc. has higher upside potential than Imunon, Inc., analysts believe BioVie, Inc. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 IMNNImunon, Inc.3 1 0 -
Is BIVI or IMNN More Risky?
BioVie, Inc. has a beta of 0.564, which suggesting that the stock is 43.606% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock BIVI or IMNN?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or IMNN?
BioVie, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. BioVie, Inc.'s net income of -$6.1M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$6.1M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns BIVI or SVRA?
Savara, Inc. has a net margin of -- compared to BioVie, Inc.'s net margin of --. BioVie, Inc.'s return on equity of -80.02% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital BIVIBioVie, Inc.-- -$0.77 $19.6M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About BIVI or SVRA?
BioVie, Inc. has a consensus price target of $12.00, signalling upside risk potential of 769.57%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that BioVie, Inc. has higher upside potential than Savara, Inc., analysts believe BioVie, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIVIBioVie, Inc.1 0 0 SVRASavara, Inc.6 0 0 -
Is BIVI or SVRA More Risky?
BioVie, Inc. has a beta of 0.564, which suggesting that the stock is 43.606% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock BIVI or SVRA?
BioVie, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioVie, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIVI or SVRA?
BioVie, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. BioVie, Inc.'s net income of -$6.1M is higher than Savara, Inc.'s net income of -$29.6M. Notably, BioVie, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioVie, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIVIBioVie, Inc.-- -- -- -$6.1M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
